Heart screening study reveals hidden amyloidosis in minorities
NCT ID NCT03812172
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study screened 646 elderly Black and Hispanic patients with heart failure to find out how many have cardiac amyloidosis, a condition where abnormal proteins build up in the heart. Researchers used a special heart scan and blood tests to detect the disease. The goal was to learn how common it is in these groups and explore links to genetics and sex.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Technetium-99m-Pyrophosphate or Technetium-99m-HydroxyMethyleneDiphosphonate (radioactive tracer for imaging)
- What this could lead to
- If successful, this could show that screening high-risk minority groups with heart imaging helps detect cardiac amyloidosis earlier, leading to better management.
- What could go wrong
- This is a completed screening study, not a treatment trial. It only measures how common the condition is, so it won't directly improve health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center/Boston University Medical Center
Boston, Massachusetts, 02118, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Harlem Hospital
New York, New York, 10037, United States
-
Yale University/Yale New Haven Medical Center
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.